Alligator Bioscience AB (publ) (STO:ATORX)
Sweden · Delayed Price · Currency is SEK | Market Cap | 16.14M -89.1% |
| Revenue (ttm) | 681.00K -98.4% |
| Net Income | -77.70M |
| EPS | -0.24 |
| Shares Out | 628.11M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,593,181 |
| Open | 0.0260 |
| Previous Close | 0.0257 |
| Day's Range | 0.0247 - 0.0272 |
| 52-Week Range | 0.0245 - 5.5950 |
| Beta | 1.19 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 26, 2026 |
About Alligator Bioscience AB
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 3 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage for the treatment of solid metastatic tumors. It also offers ALG.APV-52... [Read more]
Financial Performance
In 2025, Alligator Bioscience AB's revenue was 839,000, a decrease of -98.55% compared to the previous year's 57.72 million. Losses were -51.35 million, -78.05% less than in 2024.
Financial StatementsNews
Alligator Bioscience AB Earnings Call Transcript: Q2 2026
Strategic shift to focus on HLX22 royalties after discontinuing mitazalimab development due to KRAS inhibitor advances. Rights issue approved to fund operations until HLX22 launch, with first royalties expected in 2030. HLX22 phase III data anticipated in H2 2027.
Alligator Bioscience AB Quarterly report: Q2 2026
Alligator Bioscience AB has published its Q2 2026 quarterly earnings report on August 26, 2026.
Alligator Bioscience AB Earnings Call Transcript: Q1 2026
Mitazalimab's phase II data in pancreatic cancer supports phase III advancement, with strong investigator interest and a complementary role to emerging KRAS inhibitors. Financial runway extends to mid-Q3 2026, with additional funding needed for continued operations and trial execution.
Alligator Bioscience AB Quarterly report: Q1 2026
Alligator Bioscience AB has published its Q1 2026 quarterly earnings report on May 5, 2026.
Alligator Bioscience AB Earnings Call Transcript: Q4 2025
Landmark survival data and five complete responses in mitazalimab phase II trial support phase III readiness, while HLX22 advances with strong phase II results and global expansion. Financial runway extends to Q2 2026, with further financing and partnership options under review.
Alligator Bioscience AB Annual report: Q4 2025
Alligator Bioscience AB has published its Q4 2025 annual report on February 12, 2026.
Alligator Bioscience AB Quarterly report: Q4 2025
Alligator Bioscience AB has published its Q4 2025 quarterly earnings report on February 12, 2026.
Alligator Bioscience AB Transcript: Life Science Summit 2025
Mitazalimab shows strong survival benefits in metastatic pancreatic cancer, with phase II data supporting a clear regulatory path and partnership discussions for phase III. Expansion into other indications is underway via investigator-initiated trials, and pipeline assets offer future growth potential.
Alligator Bioscience AB Earnings Call Transcript: Q3 2025
Mitazalimab showed strong 30-month survival data in pancreatic cancer, with new phase II studies planned and a SEK 120 million rights issue providing up to nine months of runway. Cost reductions continue as the company advances partnering discussions and pipeline diversification.
Alligator Bioscience AB Quarterly report: Q3 2025
Alligator Bioscience AB has published its Q3 2025 quarterly earnings report on October 23, 2025.
Alligator Bioscience AB Transcript: Investing in Life Science 2025
Mitazalimab shows strong survival benefits in metastatic pancreatic cancer, with phase III trials ready and expansion into other solid tumors planned. Financial strategy includes leveraging government-funded studies and outlicensed assets like HLX22, expected to generate significant future income.